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Pyrrole–imidazole polyamideGene ampliﬁcation and/or overexpression of the transcription factor c-MYC, which binds to the
E-box sequence (50-CACGTG-30), has been observed in many human tumors. In this study, we have
designed 5 pyrrole–imidazole (PI) polyamides recognizing E-box, and found that, among them,
Myc-6 signiﬁcantly suppresses malignant phenotypes of human osteosarcoma MG63 cells both
in vitro and in vivo. Intriguingly, knockdown of the putative Myc-6 target MALAT1 encoding long
noncoding RNA remarkably impaired cell growth of MG63 cells. Collectively, our present ﬁndings
strongly suggest that Myc-6 exerts its tumor-suppressive ability at least in part through the speciﬁc
down-regulation of MALAT1.
 2014 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Osteosarcoma is the most common primary malignant bone tu-
mor in adolescents and young adults [1]. The curative approach to
osteosarcoma includes surgery and chemotherapy. When surgery
is not feasible, patients are sometimes subjected to radiotherapy.
In the general protocol, 10–12 weeks of neoadjuvant chemother-
apy followed by resection and adjuvant chemotherapy is per-
formed to minimize trauma [2]. Although 10-year disease-free
survival is around 60% of patients without metastasis, over 30%
of the patients suffer metastatic disease at diagnosis [3]. Despiteseveral improvements in the curative protocols, the actual survival
trends of osteosarcoma have not been substantially improved over
the past 20 years. To overcome the malignant osteosarcoma, the
alternative treatments such as hormonal therapy, gene therapy
and immune therapy are now under investigation, instead of the
conventional chemotherapy, however, the efﬁcacies of those alter-
native therapeutic strategies are limited and vary among patients
[1]. Thus, the development of a novel approach should be required
to improve the prognosis of the patients.
MYC family including c-MYC, N-MYC and L-MYC, has been
shown to be one of the most frequently altered oncogenes involved
in many malignancies. Indeed, the aberrant activation of MYC is
detectable in approximately 70% of human cancers [4]. MYC acts
as a nuclear sequence-speciﬁc transcription factor and exerts its
transcriptional activity through the formation of the heterodimeric
complex with MAX [5,6]. This MYC/MAX complex speciﬁcally
binds to the consensus motif termed E-box (50-CACGTG-30) and
M. Taniguchi et al. / FEBS Open Bio 4 (2014) 328–334 329transactivates its target genes implicated in the crucial cellular
processes such as cell cycle regulation, proliferation, metabolism
and mitochondrial biogenesis [5].
Ampliﬁcation of c-MYC has been found in musculoskeletal neo-
plasms including osteosarcoma, chondrosarcoma and soft-tissue
sarcoma [7–9]. It has been also shown that c-MYC is ampliﬁed in
several osteosarcoma-derived cell lines, which are sometimes
resistant to anti-cancer drugs such as doxorubicin and methotrex-
ate [10]. Notably, knockdown of c-MYC resulted in a marked
enhancement of sensitivity to cisplatin in osteosarcomaMG63 cells
[11]. Since these ﬁndings indicate that the ampliﬁcation of c-MYC
plays a pivotal role in the regulation of osteosarcoma development
and acquisition of chemo-resistance, molecule(s) targeting c-MYC
and/or E-box might become a novel and attractive chemotherapeu-
tic drug.
Pyrrole–imidazole (PI) polyamides, which have been developed
from the DNA-binding antibiotics distamycin A, are small synthetic
chemicals composed of the aromatic amino acids N-methylpyrrole
(Py) and N-methylimidazole (Im) [12]. According to Dervan’s
results, PI polyamides bound to the double-strand DNA in a se-
quence-speciﬁc manner and suppressed the transcription of their
target genes. A combination of PI polyamides recognized the spe-
ciﬁc DNA base pairs, (Im/Py, Py/Im and Py/Py pairs bind to G–C,
C–G, and A–T/T–A, respectively). A concatenation of these pairs
made it possible to bind to a variety of speciﬁc DNA sequences.
Since PI polyamides were efﬁciently delivered to cell nuclei with-
out any speciﬁc drug-delivery systems, they might be powerful
materials to develop gene-speciﬁc silencers [13]. Recently, we have
generated various types of PI polyamides to down-regulate the
expression of their target genes. For example, PI polyamide target-
ing the consensus activator protein-1 (AP-1)-binding site of the
TGF-b1 promoter signiﬁcantly inhibited its expression [14]. Addi-
tionally, PI polyamide recognizing AP-1-binding site within the
promoter of matrix metalloproteinase (MMP)-9 gene markedly re-
duced its expression level, and thereby strongly inhibiting the
migration and invasion of human breast cancer cells in vitro and
also abrogating the metastasis in vivo [15].
In this study, we have generated 5 PI polyamides recognizing
E-box and found that the PI polyamide termed Myc-6 suppresses
the malignant phenotypes of human osteosarcoma MG63 cells at
least in part through the speciﬁc down-regulation of MALAT1.
2. Materials and methods
2.1. Synthesis of PI polyamide targeting E-box
PI polyamides targeting E-box were designed as shown in
Fig. 1A and synthesized as described previously [16]. All of the PI
polyamides except for Myc-3 were dissolved in distilled water
(at a ﬁnal concentration of 1 mM) and small aliquots were stored
at 20 C. Myc-3 was dissolved in 50% DMSO and small aliquots
were kept at 20 C.
2.2. Cell culture and WST-8 assay
Human osteosarcoma MG63 cells were purchased from Health
Science Resource Bank of Japan, and were grown in DMEM (Naka-
lai) supplemented with 10% of heat-inactivated fetal bovine serum
(FBS), 100 lg/mL of streptomycin and 100 units/mL of penicillin.
Cultures were maintained at 37 C in a CO2 incubator with a con-
trolled humidiﬁed atmosphere composed of 95% air and 5% CO2.
Cell proliferation was assessed by WST-8 assay. Cells were seeded
at a density of 200 cells/well in 96-well plate and allowed to attach
overnight. Cells were then treated with the indicated concentra-
tions of Myc-6. At the indicated time points after the treatment,medium was replaced with the fresh medium containing 1/10 vol-
umes of WST-8 reagent, and cells were further incubated for addi-
tional 1 h followed by the measurement of absorbance at 450 nm
using ARVO MX microplate reader (Perkin Elmer).
2.3. Detection of apoptosis
Apoptosis was detected by using Cell Meter™ Phosphatidiylser-
ine Apoptosis assay kit (AAT Bioquest) following the manufac-
turer’s instructions. Brieﬂy, cells were seeded at a density of
400 cells/well in 24-well glass bottom plate, and treated with the
indicated concentrations of Myc-6. Following 2 days of the treat-
ment, cells were washed in PBS once, mixed with 500 ll of assay
buffer containing Apopxin Violet 500, and incubated for 15 min
at room temperature. Cells were examined under a ﬂuorescence
microscope (Bravio 9000: KEYENCE) with 470ex/535em.
2.4. Immunoblotting
Cells were washed in PBS and lysed in RIPA buffer. Cell lysates
(10 lg of protein) were separated by 10% SDS-polyacrylamide gel
electrophoresis and transferred onto Immobilon-P membrane
(Millipore). The membrane was blocked with Blocking-one (Naka-
lai) overnight at 4 C, and then incubated with anti-caspase-3 (Cell
Signaling Technology), anti-cleaved caspase-3 (5A1E: Cell Signal-
ing Technology) or with anti-Actin (AC-15: Sigma) antibody for
1 h at room temperature, followed by the incubation with horse-
radish peroxidase (HRP)-conjugated secondary antibody (GE
Healthcare Life Sciences) for 1 h at room temperature. After wash-
ing in PBS containing 0.1% Tween 20, immuno-reactive bands were
visualized by using ECL system (Amersham Biosciences) according
to the manufacturer’s instructions.
2.5. Soft agar colony formation assay
For soft agar assay, cells (5000 cells/plate) were seeded in trip-
licate in 35-mm cell culture plates containing 0.35% agar and
DMEM supplemented with 10% FBS. After 21 days, colonies were
stained with crystal violet (WALDECK). Number of colonies with
a diameter of > 100 lmwas scored. The data shown were the aver-
age of 3 independent experiments.
2.6. Mouse xenograft model
Cells (3  106 cells) suspended in 200 ll of PBS were injected
subcutaneously into the ﬂank of 8-weeks-old male nude mice
(n = 14). When the tumor volume reached to 200 mm3, the injec-
tion of water or Myc-6 (6 mg/kg body weight) was carried out
intravenously and continued once weekly for a total of 4 treat-
ments. Tumor volume was measured once weekly until 5 weeks
after the ﬁrst treatment. All experimental procedures performed
on animals were approved by the Laboratory Animal Care Commit-
tee of Nihon University School of Medicine.
2.7. Microarray analysis
Cells were plated at a density of 2  105 cells/well in 6-well
plate, and exposed to 10 lM of Myc-6. Twenty-four hours after
the treatment, total RNA was prepared by using TRIZOL reagent
(Invitrogen) followed by re-puriﬁcation with RNAeasy kit (QIA-
GEN) according to the manufacturer’s protocols. Using Total RNA
(100 ng), biotin-labeled cRNA probes were synthesized and hybrid-
ized to microarrays (Human Genome U133 Plus2.0: Affymetrix)
following manufacturer’s instructions. The array data (CEL ﬁles)
were quantiﬁed with the distribution free weighted method
(DFW) [17] using statistical language R (http://www.r-project)
Fig. 1. Myc-6 signiﬁcantly represses cell viability of human osteosarcoma MG63 cells. (A) Sequence comparison between the putative targets of the indicated synthetic PI
polyamides and the consensus E-box. Sequences corresponding to E-box are underlined. W indicates A or T. (B) WST-8 assay. MG63 cells were exposed to water (control),
non-speciﬁc PI polyamide (mismatch) or with the indicated PI polyamides. Six days after the treatment, cell viability was examined byWST-8 assay. Data are expressed as the
means ± SD. Differences were considered signiﬁcant at p < 0.05. ⁄p < 0.01;⁄⁄p < 0.001. (C) Chemical structure of Myc-6. (D) Schematic representation of DNA recognition by
Myc-6. Open circle, ﬁlled circle, b and Dp indicate pyrrole, imidazole, b-alanine and dimethylpropanediamine, respectively. (E) Dose and time-dependency. Cell viability was
measured by WST8 assay 3–6 days after addition of Myc-6. Differences between viability of cells treated with or without Myc-6 were considered signiﬁcant at p < 0.05.
⁄p < 0.05, ⁄⁄p < 0.01. Data were expressed as the means ± SD.
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identify the differentially expressed genes, the rank products
method [20] was applied to DFW quantiﬁed data. Probe sets with
an FDR 0.05 or lower were regarded as having different expression
levels between two groups.
2.8. Quantitative real-time PCR
Total RNA was extracted as described above. 500 ng of total
RNA were reverse-transcribed using iScript (Bio-Rad). Quantitative
real-time PCR was performed using SYBR Premix ExTaq™ system
(Takara). A mixture of cDNA derived from total RNA of MG63 cells
treated with or without various amounts of Myc-6 was used as a
reference. We then prepared dilution series of this cDNA mixture,and performed real-time PCR to obtain a standard curve for each
gene. Three independent measurements were taken and the
amounts were estimated by extrapolation from a standard curve.
Expression values were normalized against the expression of b-2-
microglobulin and used as an endogenous control. The sequences
of the primers used in this study were listed in Supplementary
Table 1.
2.9. siRNA-mediated silencing
For Knockdown of MALAT1, cells were plated at a density of
200 cells/well in a 96-well plate and allowed to attach overnight.
Cells were then transiently transfected with control siRNA or with
siRNA againstMALAT1 by using LipofectAMINE RNAiMAX transfec-
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instructions.
2.10. Statistical analysis
All values were expressed as the mean ± SE, and statistical sig-
niﬁcance was analyzed using the t-test. Signiﬁcance was set at a
p value of <0.05.
3. Results
3.1. Myc-6-mediated growth suppression of human osteosarcoma
MG63 cells
We have designed and generated 5 pyrrole–imidazole (PI)
polyamides targeting E-box to suppress malignant phenotypes of
cancerous cells (Fig. 1A). Human osteosarcoma MG63 cells were
treated with or without these PI polyamides. Six days after the
treatment, their cell viability was examined by WST-8 assay.
Among 5 PI polyamides examined, Myc-6 signiﬁcantly inhibited
MG63 cell growth and thus we have focused on Myc-6 (Fig. 1B).
Schematic drawing of Myc-6 chemical structure and its binding
to theoretical target sequence were shown in Fig. 1C and D, respec-
tively. Additional WST assays clearly demonstrated that Myc-6 re-
presses MG63 cell growth in a dose- and time-dependent manner
(Fig. 1E).Fig. 2. Myc-6-dependent induction of apoptosis. (A) Tali image-based cytometric anal
untreated. Following 72 h of Myc-6 exposure, the adherent and attached cells were collec
treated with or without Myc-6 were considered signiﬁcant at p < 0.05. ⁄p < 0.0001. The co
Forty-eight hours after the treatment, cells were incubated with apopxin violet 500 soluti
Cleavage of pro-apoptotic caspase-3. Cells were treated as in (A). Forty-eight hours after
indicated antibodies.3.2. MG63 cells undergo apoptosis in response to Myc-6
Since these results indicated that Myc-6 has an ability to pro-
hibit MG63 cell growth, we asked whether Myc-6 could affect
the cell cycle distribution. After 72 h of incubation with or without
Myc-6, both ﬂoating and adherent cells were collected and their
cell cycle distribution was examined by Tali image-based cytome-
ter. As seen in Fig. 2A, a dose-dependent massive increase in num-
ber of cells with sub-G1 or G1 DNA content was detectable, and
also number of cells bearing S phase DNA content was remarkably
reduced in a dose-dependent fashion. These observations indicate
that MG63 cells undergo apoptosis and/or G1 cell cycle arrest fol-
lowing Myc-6 exposure.
To adequately address this issue, MG63 cells treated with or
without Myc-6 were examined by using apopxin violet which
monitors the early phase of apoptosis. As shown in Fig. 2B, a
dose-dependent marked increase in number of apopxin-positive
cells was detectable in response to Myc-6. In contrast, number of
apopxin-positive cells was less than 5% without Myc-6. Under
the same experimental conditions, cell lysates were prepared and
analyzed for the presence of cleaved pro-apoptotic caspase-3 by
immunoblotting. As shown in Fig. 2C, the native caspase-3 was de-
tected in cells regardless of Myc-6 treatment, whereas cleaved cas-
pase-3 was detectable in cells exposed to 10 lM of Myc-6.
Collectively, our present ﬁndings strongly suggest that Myc-6 has
an ability to promote apoptosis in MG63 cells.ysis. MG63 cells were treated with the indicated concentrations of Myc-6 or left
ted and processed for Tali image-based cytometric analysis. Differences versus cells
lumns represent means ± SD. (B) Apopxin violet staining. Cells were treated as in (A).
on for 30 min, and then number of apopxin-positive cells was counted. ⁄p < 0.01. (C)
the treatment, cell lysates were prepared and analyzed by immunoblotting with the
Table 1
List of genes down-regulated by the treatment with Myc-6.
FDR
(%)
Gene
symbol
Gene name
0.00 NEAT1 Nuclear paraspeckle assembly transcript 1
0.17 DEPDC6 DEP domain containing 6
0.14 NEAT1 Nuclear paraspeckle assembly transcript 1
0.38 COL14A1 Collagen, type XIV, alpha 1
0.40 MALAT1 Metastasis associated lung adenocarcinoma transcript 1
1.00 MMP1 Matrix metallopeptidase 1 (interstitial collagenase)
1.23 RNF145 Ring ﬁnger protein 145
1.21 MALAT1 Metastasis associated lung adenocarcinoma transcript 1
1.20 COL3A1 Collagen, type III, alpha 1
1.19 LAMA4 Laminin, alpha 4
2.42 NEAT1 Nuclear paraspeckle assembly transcript 1
2.65 CYP1B1 Cytochrome P450, family 1, subfamily B, polypeptide 1
2.95 C5orf24 Chromosome 5 open reading frame 24
3.67 COL3A1 Collagen, type III, alpha 1
4.04 SFRP1 Secreted frizzled-related protein 1
4.35 ELK4 ELK4, ETS-domain protein (SRF accessory protein 1)
4.22 BE466173 RNA binding motif protein 39
4.86 TAF15 TAF15 RNA polymerase II, TATA box binding protein
(TBP)-associated factor
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in vivo
Considering that Myc-6 has a potential pro-apoptotic activity, it
is likely that Myc-6 might exert tumor-suppressive ability in vitro
and in vivo. To address this issue, MG63 cells were plated onto soft
agar medium containing the indicated concentrations of Myc-6.
Three weeks after the treatment, number of colonies with a diam-
eter of > 100 lm was scored. The number of colonies was signiﬁ-
cantly decreased in response to 5 or 10 lM of Myc-6 as
compared to that of control cells (Fig. 3A), suggesting that Myc-6
prohibits anchorage-independent growth of MG63 cells.
To examine the possible effect of Myc-6 in vivo, we injected
MG63 cells subcutaneously into each anterior ﬂank region of athy-
mic nude mice. When tumor volume reached to 200 mm3, mice
were randomly divided into two groups. Experimental group re-
ceived 6 mg/kg of Myc-6 intravenously once a week. Control group
similarly received water. At the indicated time points after the ﬁrst
administration, tumor volume was measured. Four weeks after the
treatment, mice were sacriﬁced. Consistent with the results ob-
tained from soft agar colony formation assay, a remarkable reduc-
tion of tumor volume was observed in Myc-6-treated mice relative
to that of control mice (Fig. 3B). The representative pictures were
shown in Fig. 3C. These results strongly suggest that Myc-6 pos-
sesses tumor-suppressive activity in vivo.
3.4. MALAT1 is a putative Myc-6-target gene
To elucidate the precise molecular mechanism(s) behind Myc-
6-mediated induction of apoptosis and suppression of tumorFig. 3. Tumor-suppressive activity of Myc-6 in vivo. (A) Anchorage-independent growth
concentrations of Myc-6. Three weeks after Myc-6 treatment, number of colonies with a d
⁄p < 0.01. The columns represent means ± SD. (B and C) Immuno-deﬁcient nude mice b
intravenously with or without Myc-6 (6 lg/kg) once a week. At the indicated time peri
statistically signiﬁcant. ⁄p < 0.05; ⁄⁄p < 0.01 (B). Representative photographs of tumors wgrowth, we sought to identify a putative Myc-6-target gene(s) by
using DNA microarray-based analysis. After the extensive screen-
ing, we have ﬁnally obtained 14 genes whose expression levels
were signiﬁcantly lower in Myc-6-treated MG63 cells relative to
those in untreated cells (Table 1). The close inspection of their
50-upstream regions (up to 1 kb) revealed that MALAT1, which en-
codes a long noncoding RNA [21], contains a theoretical Myc-6-tar-of MG63 cells. Cells were plated onto soft agar medium containing the indicated
iameter of >100 lMwas scored. Differences were considered signiﬁcant at p < 0.05.
earing subcutaneously developed tumors derived from MG63 cells were injected
ods after the ﬁrst injection, tumor volume was measured. p < 0.05 was considered
ere taken 4 weeks after Myc-6 injection (C).
Fig. 4. MALAT1 is one of possible target genes of Myc-6. (A) Sequence of 50-upstream region of human MALAT1 gene. The positions relative to the ﬁrst nucleotide of MALAT1
exon 1 (+1) are indicated. The putative Myc-6-target sequence is underlined, and E-box-like sequence is highlighted in gray. (B and C) Gel retardation assay. FITC-labeled
speciﬁc (MALAT1) or non-speciﬁc (Mismatch) oligonucleotide (1 lM) was incubated with water or Myc-6 (5 lM) for 1 h at 37 C. The reaction mixtures were separated by 4–
20% gradient polyacrylamide gel electrophoresis and then analyzed by LAS4000 (FUJIFILM) (B). FITC-labeled speciﬁc oligonucleotide (0.5 lM) was incubated with Myc-6
(0.5 lM) in the presence or absence of the indicated amounts of unlabeled speciﬁc (upper) or non-speciﬁc (lower) oligonucleotides. The reaction mixtures were analyzed as in
(B) (C). (D) Myc-6-mediated down-regulation ofMALAT1. MG63 cells were treated with or without the indicated concentrations of Myc-6. Twenty-four hours after treatment,
the expression level of MALAT1 was analyzed by real-time PCR. p < 0.05 was considered statistically signiﬁcant. ⁄p < 0.05; ⁄⁄p < 0.01; ⁄⁄⁄p < 0.001. The columns represent
means ± SD. (E) Knockdown of MALAT1 suppresses MG63 cell growth. MG63 cells were transfected with control siRNA or with siRNA against MALAT1. The cell viability was
assessed by WST-8 assay. ⁄⁄p < 0.001.
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251) (Fig. 4A). To verify whether Myc-6 could speciﬁcally bind
to this sequence, we have performed gel retardation assay. FITC-
labeled double-strand oligonucleotide corresponding to the
above-mentioned MALAT1 sequence or the unrelated sequence
(Mismatch, Supplementary Table 2) was generated, incubated with
or without Myc-6 and the reaction mixtures were separated by
polyacrylamide gel electrophoresis. Unlike the non-speciﬁc oligo-
nucleotide, a deﬁnite mobility shift of the speciﬁc oligonucleotide
was observed in the presence of Myc-6 compared to that in the
absence of Myc-6 (Fig. 4B). Furthermore, this mobility shift was
clearly inhibited by the excess amount of speciﬁc oligonucleotide
but not by non-speciﬁc one (Fig. 4C), indicating that Myc-6 specif-
ically binds to its theoretical target site located within 50-upstream
region of MALAT1.
We then investigated whether Myc-6 could reduce the expres-
sion level of MALAT1 by real-time PCR. Consistent with the resultsobtained from the microarray analysis, Myc-6 exposure led to a
dose-dependent decrease in the expression level of MALAT1 in
MG63 cells (Fig. 4D). Finally, we examined whether MALAT1 could
be involved in the regulation of Myc-6-mediated growth suppres-
sion by employing siRNA-mediated knockdown of MALAT1. MG63
cells were transfected with control siRNA or with siRNA against
MALAT1. As shown in Fig. 4E, a marked reduction in cell viability
was observed in MALAT1-knockdown cells relative to that in con-
trol cells. Taken together, our present ﬁndings strongly suggest
that E-box-targeting PI polyamide Myc-6 might exerts its growth-
and tumor-suppressive activity at least in part through the speciﬁc
down-regulation of MALAT1.
4. Discussion
In this study, we have found for the ﬁrst time that Myc-6, a PI
polyamide targeting E-box, efﬁciently suppresses malignant phe-
334 M. Taniguchi et al. / FEBS Open Bio 4 (2014) 328–334notypes of human osteosarcoma MG63 cells both in vitro and
in vivo, which might be at least in part due to Myc-6-mediated spe-
ciﬁc down-regulation of MALAT1. As expected, MALAT1 promoter
region possessed the theoretical Myc-6-binding sequence contain-
ing E-box-like motif. Thus, it is likely that PI polyamide-mediated
speciﬁc targeting E-box might become an attractive strategy to de-
velop novel anti-tumor drug(s) for the treatment of osteosarcoma.
The development of a small synthetic chemical compound(s),
which could block oncogenic signaling pathway, would be ideal
as a cancer therapeutic. Several challenges have persisted with re-
spect to drug discovery, including virtual screening of large com-
pound datasets based on computer-aided drug design. Among
them, evidence is accumulating that PI polyamide-mediated gene
silencing is an alternative and attractive approach to repress malig-
nant phenotypes of tumors [15]. In the current study, we have syn-
thesized 5 PI polyamides targeting E-box according to the general
sequence recognition rule for PI polyamides [12]. Among them,
Myc-6 displayed an ability to reduce the viability and anchorage-
independent growth of MG63 cells in vitro. Moreover, administra-
tion of Myc-6 markedly suppressed MG63 cells-derived tumor
growth in vivo. Of note, there were no signiﬁcant changes in body
weight between Myc-6-treated and untreated groups of healthy
mice, indicating there exists no toxicity of the treatment (data
not shown). Additionally, close inspection of their internal organs
such as liver, kidney and lung revealed that no morphological
changes can be found between them (data not shown). Collec-
tively, it is likely that Myc-6 possesses potential tumor-suppressive
function without any severe side effects. However, it should be
noted that the remaining 4 PI polyamides examined appear to be
biologically insufﬁcient, as no remarkable reduction in cell viability
was observed. Although the precise root of this problem has not
yet been known, it might be due to their lack of sequence-speciﬁc-
ity and/or efﬁcient nuclear access. Further studies should be re-
quired to improve the molecular design of PI polyamides.
Another ﬁnding of the present study was thatMALAT1 encoding
a long noncoding RNA might be one of Myc-6-target genes. Consis-
tent with our observations, it has been shown that MALAT1 is up-
regulated in several human solid tumors and its aberrant higher
expression level is tightly linked to tumor metastasis and recur-
rence [22]. Notably, forced expression of MALAT1 enhanced tumor
formation in nude mice, while depletion of MALAT1 in cancerous
cells reduced their tumorigenicity [23]. These ﬁndings suggest that
MALAT1 has an oncogenic function, however, the precise molecular
basis has been elusive. Recently Tripathi et al. described that deple-
tion of MALAT1 leads to an induction of tumor suppressor p53
along with its targets such as p21WAF1 and GADD45, indicating that
p53 and/or another p53 family members such as p73 might be a
downstreammediator ofMALAT1 [24]. Further experiments should
be required to adequately address howMALAT1 could contribute to
Myc-6-dependent tumor suppression.
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